Increased hepatic expression is a major determinant of serum alanine aminotransferase elevation in mice with nonalcoholic steatohepatitis

Liver International

Volumn 29, Issue 3, 2009, Pages 337-343

  Liu, Rui ^a   Pan, Xiaomin ^a   Whitington, Peter F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alanine aminotransferase; Experimental fatty liver disease; NAFLD NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLINE; MESSENGER RNA; METHIONINE;

A J MOUSE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVITY; ENZYME INDUCTION; EXPERIMENTAL MOUSE; FEMALE; HEPATITIS; LIVER CELL; LIVER NECROSIS; MOLECULAR MECHANICS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION;

ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DNA PRIMERS; FATTY LIVER; FEMALE; LIVER; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 59849106094     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01862.x     Document Type: Article

References (46)

1. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002; 123: 1367-84.
2. Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol 1978; 70: 248-58.
3. Sherman KE. Alanine aminotransferase in clinical practice. A review. Arch Intern Med 1991; 151: 260-5.
4. Rivera-Coll A, Fuentes-Arderiu X, Diez-Noguera A. Circadian rhythms of serum concentrations of 12 enzymes of clinical interest. Chronobiol Int 1993; 10: 190-200.
5. Sohocki MM, Sullivan LS, Harrison WR, et al. Human glutamate pyruvate transaminase (GPT): Localization to 8q24.3, cDNA and genomic sequences, and polymorphic sites. Genomics 1997; 40: 247-52.
6. Yang RZ, Blaileanu G, Hansen BC, Shuldiner AR, Gong DW. cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase. Genomics 2002; 79: 445-50.
7. Lindblom P, Rafter I, Copley C, et al. Isoforms of alanine aminotransferases in human tissues and serum - differential tissue expression using novel antibodies. Arch Biochem Biophys 2007; 466: 66-77.
8. Jadhao SB, Yang RZ, Lin Q, et al. Murine alanine aminotransferase: CDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology 2004; 39: 1297-302.
9. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-4.
10. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-9.
11. Iacobellis A, Marcellini M, Andriulli A, et al. Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World J Gastroenterol 2006; 12: 7821-5.
12. Burgert TS, Taksali SE, Dziura J, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: Associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 2006; 91: 4287-94.
13. Hickman IJ, Whitehead JP, Prins JB, Macdonald GA. Raised alanine transaminase and decreased adiponectin are features of the metabolic syndrome in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 438-40.
14. Oliveira AC, Oliveira AM, Almeida MS, Silva AM, Adan L, Ladeia AM. Alanine aminotransferase and high sensitivity C-reactive protein: correlates of cardiovascular risk factors in youth. J Pediatr 2008; 152: 337-42.
15. Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: The Bogalusa Heart Study. Metabolism 2007; 56: 792-8.
16. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-6.
17. Van Der Poorten D, Kenny DT, Butler T, George J. Liver disease in adolescents: A cohort study of high-risk individuals. Hepatology 2007; 46: 1750-8.
18. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21: 89-104.
19. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004; 40: 47-51.
20. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004; 287: G264-73.
21. Sahai A, Malladi P, Pan X, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: Role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1035-43.
22. Sahai A, Pan X, Paul R, Malladi P, Kohli R, Whitington PF. Roles of phosphatidylinositol 3-kinase and osteopontin in steatosis and aminotransferase release by hepatocytes treated with methionine-choline-deficient medium. Am J Physiol Gastrointest Liver Physiol 2006; 291: G55-62.
23. Kohli R, Pan X, Malladi P, Wainwright MS, Whitington PF. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J Biol Chem 2007; 282: 21327-36.
24. Dunn M, Martins J, Reissmann KR. The disappearance rate of glutamic oxalacetic transaminase from the circulation and its distribution in the body's fluid compartments and secretions. J Lab Clin Med 1958; 51: 259-65.
25. Kim YS. The half-life of alanine aminotransferase and of total soluble protein in livers of normal and glucocorticoid-treated rats. Mol Pharmacol 1969; 5: 105-8.
26. Salinas M, Wallace R, Grisolia S. Comparative studies in vivo and in vitro of rat-liver enzymes. Eur J Biochem 1974; 44: 375-81.
27. Ussery XT, Henar EL, Black DD, Berger S, Whitington PF. Acute liver injury after protracted seizures in children. J Pediatr Gastroenterol Nutr 1989; 9: 421-5.
28. Gores GJ, Herman B, Lemasters JJ. Plasma membrane bleb formation and rupture: A common feature of hepatocellular injury. Hepatology 1990; 11: 690-8.
29. Kohli R, Harris DC, Whitington PF. Relative elevations of serum alanine and aspartate aminotransferase in muscular dystrophy. J Pediatr Gastroenterol Nutr 2005; 41: 121-4.
30. Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 415-24.
31. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75.
32. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003; 39: 756-64.
33. Ota T, Takamura T, Kurita S, et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007; 132: 282-93.
34. Yamaguchi K, Yang L, Mccall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-74.
35. Yamaguchi K, Yang L, Mccall S, et al. Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology 2008; 47: 625-35.
36. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123-32.
37. Thulin P, Rafter I, Stockling K, et al. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol Appl Pharmacol 2008; 231: 1-9.
38. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-43.
39. Otogawa K, Kinoshita K, Fujii H, et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: Implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007; 170: 967-80.
40. Wieckowska A, Zein NN, Yerian LM, Lopez AR, Mccullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
41. Ramalho RM, Cortez-Pinto H, Castro RE, et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2006; 18: 21-9.
42. Diehl AM. Lessons from animal models of NASH. Hepatol Res 2005; 33: 138-44.
43. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-17.
44. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005; 10: 3093-9.
45. Solter PF, Wollenberg GK, Huang X, Chu FS, Runnegar MT. Prolonged sublethal exposure to the protein phosphatase inhibitor microcystin-LR results in multiple dose-dependent hepatotoxic effects. Toxicol Sci 1998; 44: 87-96.
46. Solter P, Liu Z, Guzman R. Decreased hepatic ALT synthesis is an outcome of subchronic microcystin-LR toxicity. Toxicol Appl Pharmacol 2000; 164: 216-20.